<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00559312</url>
  </required_header>
  <id_info>
    <org_study_id>SCO110755</org_study_id>
    <nct_id>NCT00559312</nct_id>
  </id_info>
  <brief_title>The Effect of Fluticasone/Salmeterol Combination on Exertional Breathlessness in Patients With Mild COPD</brief_title>
  <official_title>A 6-week Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Fluticasone 250μg/Salmeterol 50μg Combination (FSC 250/50) on Exertional Dyspnea in Patients With Symptomatic Mild COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen's University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Queen's University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Even patients with milder COPD can have significant physiological abnormalities which become
      more pronounced during exercise, leading to intolerable breathing discomfort (dyspnea). While
      there is a compelling physiological rationale for the efficacy of inhaled
      corticosteroid/long-acting bronchodilator combination therapy [i.e., fluticasone
      250μg/salmeterol 50μg (FSC250/50)] in moderate to severe COPD, little information is
      available on the potential impact of this therapy in milder symptomatic disease. This study
      will be the first to explore mechanisms of dyspnea and activity limitation in milder COPD and
      will determine if there is a sound physiological rationale for the use of FSC as therapy for
      this subpopulation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dyspnea intensity (Borg rating at a standardized time during exercise)</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exercise endurance time</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurements of small airway function</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise measurements of ventilation, breathing pattern, operating lung volumes and respiratory mechanics</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>FSC 250/50</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fluticasone 250μg/salmeterol 50μg combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matched placebo inhaler</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone/salmeterol combination</intervention_name>
    <description>Diskus inhaler, fluticasone 250μg/salmeterol 50μg, twice daily, 6-week duration</description>
    <arm_group_label>FSC 250/50</arm_group_label>
    <other_name>Advair 250/50</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo Diskus inhaler, twice daily, 6-week duration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable mild COPD,

          -  FEV1/FVC&lt;0.7 and FEV1&gt;60% predicted,

          -  Activity-related dyspnea (i.e., Baseline Dyspnea Index focal score &lt;9, MRC dyspnea
             scale &gt;2),

          -  Cigarette smoking history ≥20 pack-years.

        Exclusion Criteria:

          -  Presence of a significant disease other than COPD that could contribute to dyspnea and
             exercise limitation,

          -  Important contraindications to clinical exercise testing,

          -  Use of daytime oxygen,

          -  History of Asthma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>41 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis E O'Donnell, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen's University and Kingston General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Respiratory Investigation Unit at Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2007</study_first_submitted>
  <study_first_submitted_qc>November 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2007</study_first_posted>
  <last_update_submitted>December 14, 2012</last_update_submitted>
  <last_update_submitted_qc>December 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen's University</investigator_affiliation>
    <investigator_full_name>Dr. Denis O'Donnell</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>mild COPD</keyword>
  <keyword>dyspnea</keyword>
  <keyword>exercise</keyword>
  <keyword>combination therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

